ID   NCC-TGCT1-C1
AC   CVCL_A9YZ
DR   Wikidata; Q102114581
RX   PubMed=32886306;
WW   https://en.cellline.jp/product/ncc-tgct1-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: 30 hours (PubMed=32886306).
CC   Sequence variation: Gene fusion; HGNC; 2213; COL6A3 + HGNC; 2432; CSF1; Name(s)=COL6A3-CSF1 (PubMed=32886306).
CC   Derived from site: In situ; Hip, tendon sheath; UBERON=UBERON_0001486+UBERON_0000304.
ST   Source(s): PubMed=32886306
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 8,9
ST   D16S539: 9,12
ST   D21S11: 30,31.2
ST   D5S818: 12
ST   D7S820: 9,12
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C6535; Malignant tenosynovial giant cell tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   40Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 30-01-24; Version: 7
//
RX   PubMed=32886306; DOI=10.1007/s13577-020-00425-8;
RA   Noguchi R., Yoshimatsu Y., Ono T., Sei A., Hirabayashi K., Ozawa I.,
RA   Kikuta K., Kondo T.;
RT   "Establishment and characterization of a novel cell line,
RT   NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell
RT   tumor.";
RL   Hum. Cell 34:254-259(2021).
//